PledPharma AB | Innovative, unique and integrated competence in pharmaceutical drug development with focus on improving treatments for severe diseases with substantial unmet medical need where alternative treatments does not exist

PledPharma has an innovative, unique and integrated competence in pharmaceutical drug development with focus on improving treatments for severe diseases with substantial unmet medical need where alternative treatments does not exist.

More about PledPharma

Pipeline

Annual General Meeting May 7

Press Releases

Regulatory

October 16, 2019

PledPharma approved for listing on Nasdaq Stockholm

Regulatory

October 9, 2019

PledPharma and Solasia enter a second license agreement for the development and commercialisation of PledOx® in Asia, targeting neuropathy caused by taxanes and any other chemotherapy

Regulatory

August 21, 2019

Half-Year report January-June 2019

Latest Report

August 21, 2019

Latest interim report

March 29, 2019

Annual report 2018

Latest presentation

September 2, 2019

Company presentation September 2019

Calendar and upcoming reports

October 23, 2019

Interim report, Jan-Sep

November 11-13, 2019

Bio Europe, Hamburg

November 20-21, 2019

Jefferies, London

January 13-15, 2020

JP Morgan, San Fransisco

February 18, 2020

Year end report

Contact us

Address: Grev Turegatan 11 C, 114 46 Stockholm, Sweden

Phone: +46 8 679 72 10

E-mail: info@pledpharma.com